November’s American Heart Association (AHA) Scientific Sessions in Orlando, Florida, welcomed more than 27,000 attendees across a variety of disciplines associated with cardiology. Although many trials had generally negative outcomes, presenters emphasized their positive implications for future research and clinical practice. The International Congress on Stem Cells and Myocardial Regeneration, running in conjunction with the Scientific Sessions, also attracted high interest.
One of the key sessions at last spring’s American College of Cardiology (ACC) meeting, the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluations (COURAGE) trial, showed no statistical significance in...